- Conditions
- Advanced Non-squamous Non-small-cell Lung Cancer
- Interventions
- ERAS-007, ERAS-601, Osimertinib, Sotorasib
- Drug
- Lead sponsor
- Erasca, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 11
- States / cities
- Duarte, California • Orange, California • Santa Monica, California + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 673–696
of 4,494
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Interventions
- Cisplatin, CT, Docetaxel, FDG, FLT, PET/CT, Surgery
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 19 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Columbus, Ohio
- Conditions
- Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer, NSCLC, Colorectal Cancer (CRC), Myxofibrosarcoma (MFS), Solitary Fibrous Tumors, Dedifferentiated Liposarcoma, Undifferentiated Pleomorphic Sarcoma (UPS), Leiomyosarcoma, Leiomyosarcoma (LMS), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Gastric / Gastroesophageal Junction Adenocarcinoma
- Interventions
- OKN4395, Pembrolizumab, Fasting, Fed, H2 Receptor Antagonist
- Drug · Combination Product · Other
- Lead sponsor
- Epkin
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Beverly Hills, California • Santa Monica, California • Houston, Texas
- Conditions
- Breast Cancer, Skin Cancer
- Interventions
- CLIPT patch
- Device
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- bevacizumab, Erlotinib
- Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 7
- States / cities
- Galloway, New Jersey • Mount Holly, New Jersey • Paoli, Pennsylvania + 2 more
- Conditions
- Non Small Cell Lung Cancer (NSCLC)
- Interventions
- Nivolumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,428 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 127
- States / cities
- Mobile, Alabama • Goodyear, Arizona • Phoenix, Arizona + 117 more
- Conditions
- AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma, HIV Infection, Kaposi Sarcoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Malignant Neoplasm, Refractory Classic Hodgkin Lymphoma, Refractory Malignant Neoplasm, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Melanoma
- Interventions
- Antiretroviral Therapy, Biopsy, Biospecimen Collection, Computed Tomography, Pembrolizumab, Positron Emission Tomography
- Drug · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- docetaxel (Taxotere®), ZD1839
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2012
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Lung Cancer, Esophageal Cancer
- Interventions
- Not listed
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
- Interventions
- Sigvotatug Vedotin, Pembrolizumab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 714 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 85
- States / cities
- Fairbanks, Alaska • Fullerton, California • Golden, Colorado + 57 more
- Conditions
- Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Colorectal Cancer, Endometrial Cancer, Urothelial Carcinoma (UC), Breast Cancer
- Interventions
- STRO-006, Pembrolizumab
- Drug
- Lead sponsor
- Sutro Biopharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 6
- States / cities
- Orlando, Florida • Boston, Massachusetts • Oklahoma City, Oklahoma + 3 more
- Conditions
- Lung Cancer
- Interventions
- rubitecan
- Drug
- Lead sponsor
- Astex Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2004
- U.S. locations
- 1
- States / cities
- Dublin, California
- Conditions
- Small Cell Lung Cancer
- Interventions
- Fenretinide
- Drug
- Lead sponsor
- SciTech Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Detroit, Michigan
- Conditions
- Metastatic Lung Cancer
- Interventions
- Cryoablation
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Detroit, Michigan • Rochester, Minnesota
- Conditions
- Lung Cancer, Driver Mutation
- Interventions
- Low Dose CT Scan
- Diagnostic Test
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,753 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Carcinoma, Non-small-cell Lung
- Interventions
- erlotinib (Tarceva) and bexarotene (Targretin)
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Hematopoietic and Lymphoid System Neoplasm, Malignant Breast Neoplasm, Malignant Head and Neck Neoplasm, Malignant Solid Neoplasm, Malignant Thoracic Neoplasm
- Interventions
- Questionnaire Administration, Telephone-Based Intervention, Virtual Technology Intervention
- Other · Behavioral
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Nivolumab, Ipilimumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 9
- States / cities
- San Francisco, California • Lincoln, Nebraska • Hackensack, New Jersey + 6 more
- Conditions
- Neuroendocrine Cancer, Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Gastric Cancer
- Interventions
- thermochemotherapy, Cisplatin, Gemcitabine, Interferon-a
- Other · Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Solid Tumor, Adult
- Interventions
- LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER, Pembrolizumab - anti-PD-1 antibody
- Drug · Biological
- Lead sponsor
- Linnaeus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 10
- States / cities
- Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 5 more
- Conditions
- Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Renal Cell Carcinoma, Nasopharyngeal Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer
- Interventions
- P-MUC1C-ALLO1 CAR-T cells, Rimiducid
- Biological · Drug
- Lead sponsor
- Poseida Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2039
- U.S. locations
- 14
- States / cities
- Irvine, California • Los Angeles, California • San Diego, California + 11 more
- Conditions
- Advanced or Metastatic Solid Tumor
- Interventions
- PLN-101095, Pembrolizumab
- Drug
- Lead sponsor
- Pliant Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 20
- States / cities
- New Haven, Connecticut • Washington D.C., District of Columbia • Atlanta, Georgia + 15 more
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck, Cancer of Rectum, Cancer of Kidney, Cancer of Esophagus, Cancer of Colon, Cancer Skin, Cancer of Cervix, Cancer, Metastatic, Cancer of Larynx, Cancer of Neck, Cancer of Lung, Cancer of Brain and Nervous System, Cancer of Vulva, Disseminated, Cancer of Pancreas, Sarcoma, GIST, Small-cell Lung Cancer, Adenocarcinoma Lung, Cancer of Prostate, Cancer, Advanced, Adrenal Cancer, Testicular Cancer, Uterine Cancer, Bronchoalveolar Cell Lung Cancer, Cancer Unknown Primary, Glioblastoma Multiforme, Oligodendroglioma, Breast Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma, Cholangiocarcinoma, Squamous Cell Carcinoma, Transitional Cell Carcinoma, Cancer, Other, Cancer, Anal, Melanoma, Cancer, Bile Duct, Cancer, Bladder, Cancer Cords Vocal, Cancers Cell Neuroendocrine, Cancer Differentiated Poorly, Cancer, Anaplastic Thyroid
- Interventions
- Not listed
- Lead sponsor
- SpeciCare
- Industry
- Eligibility
- 1 Month to 99 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Gainesville, Georgia
- Conditions
- Clear Cell Renal Cell Carcinoma (ccRCC), Melanoma, Non-small Cell Lung Cancer (NSCLC)
- Interventions
- CB-839, Nivolumab
- Drug
- Lead sponsor
- Calithera Biosciences, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • Palo Alto, California • Aurora, Colorado + 10 more